BIVI News and Press, BioVie Inc. From 09/07/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: NicoElNino / Shutterstock.com Sidus Space (NASDAQ: SIDU ) stock is rising higher on Wednesday after the company announced an agreement with Elon Musk’s SpaceX . That agreement has Sidus Space...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a fresh press release from this morning, BioVie (NASDAQ: BIVI ) disclosed top-line results from a Phase 2 clinical trial for its Alzheimer’s disease treatment, NE3107. The results were largely positive, an...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com It’s time for another look at the biggest pre-market stock movers as we see why shares are moving Wednesday morning! Moving stocks this morning are earnings reports, cli...

BioVie Inc. ( NASDAQ: BIVI ), a biotech focused on liver and neurological diseases, added ~21% in the pre-market trading Wednesday following an announcement on results from an investigator-sponsored Phase 2 clinical trial of NE3107 in Alzheimer’s Disease (AD). Run...

Vast majority of patients saw significant improvements in the Global Rating of Change (overall impression of patient’s daily abilities) with NE3107 treatment (p<0.0001 to p<0.05). NE3107 is associated with significant improvements in cognition as evidenced by the ...

Summary Earlier June coverage of BioVie showed the company’s potential in Alzheimer’s and Parkinson’s. Since that coverage, the company seems to have been set up for success. Readouts in Phase 2 Alzheimer’s and Parkinson’s trials are now immi...

Cantor Fitzgerald analyst Charles Duncan initiated coverage of BioVie ( BIVI ) with an Overweight rating and $7 price target. The company's development strategy is based on research that suggests that neuroinflammation is a primary driver of disease progression, and believes ...

Gainers: Grove Collaborative ( GROV ) +80% . Faraday Future Intelligent Electric ( FFIE ) +30% . Bed Bath & Beyond ( BBBY ) +27% . Dakota Gold ( DC ) +21% . Bolt Biotherapeutics ( BOLT ) +20% . Miromatrix Medical ( MIRO...

Gainers: Longeveron ( LGVN ) +16% . Adverum Biotechnologies ( ADVM ) +13% . 89bio ( ETNB ) +12% . Mainz Biomed ( MYNZ ) +11% . Shineco ( SISI ) +8% . Losers: DiaMedica Therapeutics ( DMAC ) -41% . Cytom...

BioVie (NASDAQ:BIVI) on Thursday said it had won a patent for its ascites medicine BIV201 which was expected to cover treatment with it in the U.S. until 2036. BIVI stock gained 7.1% to $1.80 in premarket trading. The U.S. Patent & Trademark Office (USPTO) issued BIVI ...